Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 6 | 2018 | 488 | 1.300 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 311 | 1.280 |
Why?
|
| Carrier Proteins | 3 | 2017 | 136 | 1.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 2 | 2016 | 2 | 1.120 |
Why?
|
| Colorectal Neoplasms | 3 | 2017 | 216 | 1.090 |
Why?
|
| Glioma | 2 | 2017 | 136 | 1.030 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 409 | 1.010 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 194 | 0.880 |
Why?
|
| Neoplasms | 3 | 2018 | 692 | 0.830 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 261 | 0.830 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 638 | 0.740 |
Why?
|
| MicroRNAs | 3 | 2018 | 180 | 0.730 |
Why?
|
| Endometrial Neoplasms | 2 | 2018 | 45 | 0.700 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2017 | 21 | 0.690 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 140 | 0.640 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 4 | 0.630 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2017 | 4 | 0.600 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 456 | 0.580 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.580 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 55 | 0.570 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 25 | 0.570 |
Why?
|
| Chromosomal Instability | 1 | 2016 | 5 | 0.570 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 4 | 0.570 |
Why?
|
| Signal Transduction | 3 | 2017 | 682 | 0.560 |
Why?
|
| Autophagy | 1 | 2017 | 52 | 0.560 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 221 | 0.550 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 154 | 0.550 |
Why?
|
| NF-kappa B | 1 | 2016 | 81 | 0.540 |
Why?
|
| Apoptosis | 1 | 2017 | 352 | 0.490 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.480 |
Why?
|
| Disease Progression | 4 | 2017 | 591 | 0.480 |
Why?
|
| Down-Regulation | 3 | 2018 | 142 | 0.420 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 725 | 0.420 |
Why?
|
| Humans | 22 | 2018 | 31981 | 0.410 |
Why?
|
| Female | 15 | 2018 | 19920 | 0.340 |
Why?
|
| Cell Movement | 4 | 2016 | 169 | 0.330 |
Why?
|
| Prognosis | 6 | 2018 | 1505 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2017 | 73 | 0.310 |
Why?
|
| Mice, Nude | 3 | 2017 | 290 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2018 | 57 | 0.290 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 137 | 0.290 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2016 | 27 | 0.270 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 148 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 834 | 0.260 |
Why?
|
| Animals | 6 | 2018 | 7463 | 0.230 |
Why?
|
| Mice | 4 | 2018 | 2472 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 461 | 0.230 |
Why?
|
| Male | 8 | 2018 | 19161 | 0.210 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 3998 | 0.210 |
Why?
|
| Genes, p53 | 2 | 2018 | 23 | 0.190 |
Why?
|
| Gene Deletion | 2 | 2018 | 66 | 0.180 |
Why?
|
| Membrane Proteins | 2 | 2018 | 256 | 0.180 |
Why?
|
| Middle Aged | 7 | 2018 | 11845 | 0.170 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 34 | 0.170 |
Why?
|
| Aged | 6 | 2018 | 10332 | 0.170 |
Why?
|
| Protein Binding | 2 | 2017 | 201 | 0.170 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 170 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 761 | 0.170 |
Why?
|
| Transfection | 2 | 2016 | 191 | 0.170 |
Why?
|
| CA-125 Antigen | 1 | 2018 | 7 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 20 | 0.160 |
Why?
|
| Germ Cells | 1 | 2018 | 10 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 84 | 0.150 |
Why?
|
| beta Catenin | 1 | 2018 | 37 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 35 | 0.150 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2017 | 5 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2017 | 22 | 0.150 |
Why?
|
| Oncogene Fusion | 1 | 2017 | 1 | 0.150 |
Why?
|
| DNA Damage | 1 | 2018 | 98 | 0.150 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 5 | 0.150 |
Why?
|
| Vesicular Transport Proteins | 1 | 2017 | 10 | 0.150 |
Why?
|
| Immunoglobulins | 1 | 2017 | 15 | 0.150 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 11 | 0.150 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 16 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2017 | 35 | 0.150 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 43 | 0.150 |
Why?
|
| Clone Cells | 1 | 2017 | 36 | 0.150 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 18 | 0.150 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.150 |
Why?
|
| Adult | 4 | 2018 | 9340 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 24 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 79 | 0.140 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 12 | 0.140 |
Why?
|
| Pseudopodia | 1 | 2016 | 2 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 3 | 0.140 |
Why?
|
| Cytoskeleton | 1 | 2016 | 18 | 0.140 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2016 | 1 | 0.140 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cell Shape | 1 | 2016 | 28 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 488 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 85 | 0.140 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 73 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 34 | 0.140 |
Why?
|
| Oncogenes | 1 | 2016 | 12 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 19 | 0.140 |
Why?
|
| Base Sequence | 1 | 2017 | 251 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 94 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 99 | 0.140 |
Why?
|
| Doxycycline | 1 | 2016 | 25 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2017 | 140 | 0.140 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 114 | 0.140 |
Why?
|
| Animals, Newborn | 1 | 2016 | 115 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 322 | 0.130 |
Why?
|
| Carcinoma | 1 | 2016 | 92 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 200 | 0.130 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 247 | 0.130 |
Why?
|
| Models, Biological | 1 | 2017 | 391 | 0.120 |
Why?
|
| Young Adult | 2 | 2018 | 2607 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1267 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 496 | 0.110 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 1167 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1017 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3523 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 607 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 319 | 0.100 |
Why?
|
| Child | 1 | 2017 | 2433 | 0.090 |
Why?
|
| African Americans | 1 | 2017 | 1427 | 0.090 |
Why?
|
| Adolescent | 1 | 2017 | 3515 | 0.080 |
Why?
|
| Sulfides | 2 | 2018 | 27 | 0.070 |
Why?
|
| Caprylates | 2 | 2018 | 28 | 0.070 |
Why?
|
| RNA Interference | 2 | 2017 | 76 | 0.070 |
Why?
|
| Genotype | 2 | 2018 | 733 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 757 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 1062 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 72 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 146 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 1 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 13 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 18 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 20 | 0.040 |
Why?
|
| Protein Transport | 1 | 2018 | 74 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 37 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2018 | 22 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2018 | 19 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 41 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2018 | 50 | 0.040 |
Why?
|
| Cytarabine | 1 | 2018 | 55 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2017 | 6 | 0.040 |
Why?
|
| Serine | 1 | 2017 | 10 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 11 | 0.040 |
Why?
|
| Acetylation | 1 | 2017 | 15 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2018 | 220 | 0.040 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 3 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 27 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 71 | 0.040 |
Why?
|
| CpG Islands | 1 | 2017 | 45 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2018 | 70 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 261 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 122 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2018 | 108 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 25 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 167 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 30 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 12 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 120 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 20 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 31 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 61 | 0.040 |
Why?
|
| Leukocytes | 1 | 2017 | 57 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 104 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 52 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 265 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 47 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 154 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2017 | 228 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 45 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 59 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 82 | 0.040 |
Why?
|
| Cell Line | 1 | 2018 | 435 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 259 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 33 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2016 | 51 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2017 | 85 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 104 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 594 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mitochondria | 1 | 2018 | 186 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 130 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 80 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 158 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 547 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 532 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 496 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1821 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 598 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 2151 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 3315 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 3867 | 0.020 |
Why?
|